Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Clinical Research

Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience

Abstract

Background and aims

Randomized clinical trials have proven the efficacy and safety of Food and Drug Administration (FDA) approved anti-obesity medications (AOMs) for long-term use. It is unclear whether these outcomes can be replicated in real-world clinical practice where clinical complexities arise. The aim of this study was to evaluate the effectiveness and side effects of these medications in real-world multidisciplinary clinical practice settings.

Methods

We reviewed the electronic medical records (EMR) of patients with obesity who were prescribed an FDA-approved AOM for long-term use in academic and community multidisciplinary weight loss programs between January 2016 and January 2020.

Intervention

We assessed percentage total body weight loss (%TBWL), metabolic outcomes, and side effect profile up to 24 months after AOM initiation.

Results

The full cohort consisted of 304 patients (76% women, 95.2% White, median age of 50 years old [IQR, 39–58]). The median follow-up time was 9.1 months [IQR, 4.2–14.1] with a median number of 3 visits [IQR, 2–4]. The most prescribed medication was phentermine/topiramate extended-release (ER) (51%), followed by liraglutide (26.3%), bupropion/naltrexone sustained-release (SR) (16.5%), and lorcaserin (6.2%). %TBWL was 5.0%, 6.8%, 9.3%, 10.3%, and 10.5% at 3, 6, 12, 18, and 24 months. 60.2% of the entire cohort achieved at least 5% TBWL. Overall, phentermine/topiramate-ER had the most robust weight loss response during follow-up, with the highest %TBWL at 12 months of 12.0%. Adverse events were reported in 22.4% of patients. Only 9% of patients discontinued the medication due to side effects.

Conclusions

AOMs resulted in significant long-term weight loss, that was comparable to outcomes previously reported in clinical trials.

Your institute does not have access to this article

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1: Follow-up flowchart.
Fig. 2: Weight loss outcomes after anti-obesity medication initiation.

References

  1. Ogden CL, Carroll MD, Fryar CD, Flegal KM. Prevalence of obesity among adults and youth: United States, 2011–2014. NCHS Data Brief. 2015;219:1–8.

    Google Scholar 

  2. Waters H, Graf M. America’s obesity crisis. The Health and Economic Costs of Excess Weight. Santa Monica, California: Milken Institute; 2018.

  3. Su W, Huang J, Chen F, Iacobucci W, Mocarski M, Dall TM, et al. Modeling the clinical and economic implications of obesity using microsimulation. J Med Econ. 2015;18:886–97.

    CAS  Article  Google Scholar 

  4. Kim DD, Basu A. Estimating the medical care costs of obesity in the United States: systematic review, meta-analysis, and empirical analysis. Value Health. 2016;19:602–13.

    Article  Google Scholar 

  5. Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med. 2017;376:1492.

    Article  Google Scholar 

  6. Acosta A, Streett S, Kroh MD, Cheskin LJ, Saunders KH, Kurian M, et al. White paper AGA: POWER - practice guide on obesity and weight management, education, and resources. Clin Gastroenterol Hepatol. 2017;15:631–49. e10.

    Article  Google Scholar 

  7. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63:2985–3023.

    Article  Google Scholar 

  8. Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, et al. Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:342–62.

    CAS  Article  Google Scholar 

  9. Sharretts J, Galescu O, Gomatam S, Andraca-Carrera E, Hampp C, Yanoff L. Cancer risk associated with lorcaserin - the FDA’s review of the CAMELLIA-TIMI 61 trial. N Engl J Med. 2020;383:1000–2.

    CAS  Article  Google Scholar 

  10. CllinicalTrials.gov. A research study of NNC0165-1562 and semaglutide in people who are overweight or obese. 2020. https://clinicaltrials.gov/ct2/show/NCT03574584.

  11. Lewis KH, Fischer H, Ard J, Barton L, Bessesen DH, Daley MF, et al. Safety and effectiveness of longer-term phentermine use: clinical outcomes from an electronic health record cohort. Obesity. 2019;27:591–602.

    CAS  Article  Google Scholar 

  12. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341–52.

    CAS  Article  Google Scholar 

  13. Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363:245–56.

    CAS  Article  Google Scholar 

  14. Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376:595–605.

    CAS  Article  Google Scholar 

  15. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0 mg oF Liraglutide in Weight Management. N Engl J Med. 2015;373:11–22.

    Article  Google Scholar 

  16. Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes. 2013;37:1443–51.

    CAS  Article  Google Scholar 

  17. Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes. 2012;36:843–54.

    CAS  Article  Google Scholar 

  18. Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95:297–308.

    CAS  Article  Google Scholar 

  19. Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T. et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity. 2012;20:330–42.

    CAS  Article  Google Scholar 

  20. Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA. 2016;315:2424–34.

    CAS  Article  Google Scholar 

  21. Carey TA, Stiles WB. Some problems with randomized controlled trials and some viable alternatives. Clin Psychol Psychother. 2016;23:87–95.

    Article  Google Scholar 

  22. Grudell AB, Sweetser S, Camilleri M, Eckert DJ, Vazquez-Roque MI, Carlson PJ, et al. A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults. Gastroenterology. 2008;135:1142–54.

    CAS  Article  Google Scholar 

  23. Holgerson AA, Clark MM, Ames GE, Collazo-Clavell ML, Kellogg TA, Graszer KM, et al. Association of adverse childhood experiences and food addiction to bariatric surgery completion and weight loss outcome. Obes Surg. 2018;28:3386–92.

    Article  Google Scholar 

  24. Gorgojo-Martínez JJ, Basagoiti-Carreño B, Sanz-Velasco A, Serrano-Moreno C, Almodóvar-Ruiz F. Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real-world setting: The XENSOR Study. Int J Clin Pract. 2019;73:e13399.

    Article  Google Scholar 

  25. Park JH, Kim JY, Choi JH, Park HS, Shin H-Y, Lee JM, et al. Effectiveness of liraglutide 3 mg for the treatment of obesity in a real-world setting without intensive lifestyle intervention. Int J Obes. 2021;45:776–86.

    CAS  Article  Google Scholar 

  26. Piantanida E, Gallo D, Tanda ML. Liraglutide is an effective drug for the treatment of obesity also in real life. J Endocrinol Investig. 2020;43:1827–8.

    CAS  Article  Google Scholar 

  27. Wharton S, Liu A, Pakseresht A, Nørtoft E, Haase CL, Mancini J, et al. Real-world clinical effectiveness of liraglutide 3.0 mg for weight management in Canada. Obesity. 2019;27:917–24.

    CAS  Article  Google Scholar 

  28. Ferrari F, Fierabracci P, Salvetti G, Jaccheri R, Vitti J, Scartabelli G, et al. Weight loss effect of liraglutide in real-life: the experience of a single Italian obesity center. J Endocrinol Investig. 2020;43:1779–85.

    CAS  Article  Google Scholar 

  29. Fakhreddine AY, Bagsic S, Fujioka K, Frenette CT. Safety and efficacy of pharmacologic weight loss in patients with cirrhosis. Obes Sci Pract. 2021;7:159–67.

    Article  Google Scholar 

  30. Ganguly R, Tian Y, Kong SX, Hersloev M, Hobbs T, Smolarz BG, et al. Persistence of newer anti-obesity medications in a real-world setting. Diabetes Res Clin Pract. 2018;143:348–56.

    CAS  Article  Google Scholar 

  31. Shibuya K, Ali KF, Ji X, Milinoivh A, Bauman J, Kattan MW, et al. The benefit of short-term weight loss with anti-obesity medications in real-world clinical practice. Endocr Pract. 2019;25:1022–8.

    Article  Google Scholar 

  32. Elangovan A, Shah R, Smith ZL. Pharmacotherapy for obesity—trends using a population level national database. Obes Surg. 2021;31:1105–12.

    Article  Google Scholar 

  33. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002.

    CAS  Article  Google Scholar 

  34. Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96:3067–77.

    CAS  Article  Google Scholar 

  35. Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O’Neil PM, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity. 2011;19:110–20.

    CAS  Article  Google Scholar 

  36. Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity. 2013;21:935–43.

    CAS  Article  Google Scholar 

  37. Lei XG, Ruan JQ, Lai C, Sun Z, Yang X. Efficacy and safety of phentermine/topiramate in adults with overweight or obesity: a systematic review and meta-analysis. Obesity 2021;29:985–94.

    CAS  Article  Google Scholar 

  38. Lewis KH, Fischer H, Ard J, Barton L, Bessesen DH, Daley MF, et al. Safety and effectiveness of longer-term phentermine use: clinical outcomes from an electronic health record cohort. Obesity. 2019;27:591–602.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

We would like to thank Dr. Michael Jensen for his critical feedback on the reporting of the findings and the discussion.

Author information

Authors and Affiliations

Authors

Contributions

GC, DGI, KLS, AA, and MAM conceived and design the study. MCC, MS, DH, HAL, KS, MMC, KG, MSM, MC, BAD, MDH, AA, and M.A.M coordinated data contributions. GC, DGI, KLS, OGV, AC, LC, AA, MeS, MaS, MDH analyzed the data. LC, AC, AA, and MDH produced the figures and tables. All authors contributed to the revision of the first draft, reviewed and approved the final version of the paper.

Corresponding authors

Correspondence to Maria D. Hurtado Andrade, Mohamad A. Mokadem or Andres Acosta.

Ethics declarations

Competing interests

MSM has research grants from Fresenius Kabi, Nestle, Realfood Blends, and VectivBio and is a consultant for Baxter. AA reports other from Gila Therapeutics, other from Phenomix Sciences, personal fees from Rhythm Pharmaceuticals, personal fees from General Mills, outside the submitted work. BAD has served as a consultant for Boston Scientific, Metamodix, BFKW, DyaMx, and USGI Medical, has received research support for Boston Scientific, Apollo Endosurgery, USGI, Spatz Medical, GI Dynamics, Caim Diagnostics, Aspire Bariatrics, and Medtronic, and has been a speaker for Johnson & Johnson, Endogastric Solutions, and Olympus. MC is a stockholder in Phenomix Sciences and Enterin and serves as a consultant to Takeda, Allergan, Rhythm, Kallyope, and Arena with compensation to his employer, Mayo Clinic. Other authors declare no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Calderon, G., Gonzalez-Izundegui, D., Shan, K.L. et al. Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience. Int J Obes 46, 555–563 (2022). https://doi.org/10.1038/s41366-021-01019-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41366-021-01019-6

Search

Quick links